Shenzhen Salubris Pharmaceuticals Future Growth
Future criteria checks 2/6
Shenzhen Salubris Pharmaceuticals is forecast to grow earnings and revenue by 15.5% and 14.9% per annum respectively. EPS is expected to grow by 15.5% per annum. Return on equity is forecast to be 9.2% in 3 years.
Key information
15.5%
Earnings growth rate
15.5%
EPS growth rate
| Pharmaceuticals earnings growth | 19.0% |
| Revenue growth rate | 14.9% |
| Future return on equity | 9.2% |
| Analyst coverage | Low |
| Last updated | 29 Oct 2024 |
Recent future growth updates
Recent updates
These 4 Measures Indicate That Shenzhen Salubris Pharmaceuticals (SZSE:002294) Is Using Debt Safely
Nov 11
We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings
Sep 02What Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) P/E Is Not Telling You
Aug 23Are Investors Undervaluing Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) By 21%?
Aug 02Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Not Quite Adding Up
May 22A Look At The Fair Value Of Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294)
Apr 17Is Shenzhen Salubris Pharmaceuticals (SZSE:002294) A Risky Investment?
Feb 28Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5,440 | 858 | 727 | 1,201 | 4 |
| 12/31/2025 | 4,608 | 733 | 650 | 862 | 4 |
| 12/31/2024 | 4,050 | 633 | 465 | 1,005 | 2 |
| 9/30/2024 | 3,910 | 611 | 561 | 1,158 | N/A |
| 6/30/2024 | 3,724 | 587 | 289 | 1,019 | N/A |
| 3/31/2024 | 3,569 | 569 | 262 | 944 | N/A |
| 12/31/2023 | 3,365 | 580 | 168 | 839 | N/A |
| 9/30/2023 | 3,390 | 577 | 121 | 806 | N/A |
| 6/30/2023 | 3,498 | 627 | 388 | 916 | N/A |
| 3/31/2023 | 3,434 | 611 | 402 | 931 | N/A |
| 1/1/2023 | 3,482 | 637 | 372 | 971 | N/A |
| 9/30/2022 | 3,419 | 681 | 481 | 1,032 | N/A |
| 6/30/2022 | 3,350 | 645 | 768 | 1,276 | N/A |
| 3/31/2022 | 3,228 | 616 | 726 | 1,231 | N/A |
| 1/1/2022 | 3,058 | 534 | 702 | 1,185 | N/A |
| 9/30/2021 | 2,792 | 185 | 510 | 1,063 | N/A |
| 6/30/2021 | 2,579 | 101 | 40 | 597 | N/A |
| 3/31/2021 | 2,638 | 66 | 341 | 878 | N/A |
| 12/31/2020 | 2,739 | 61 | 732 | 1,374 | N/A |
| 9/30/2020 | 3,041 | 266 | 811 | 1,408 | N/A |
| 6/30/2020 | 3,650 | 279 | 1,171 | 1,774 | N/A |
| 3/31/2020 | 4,148 | 544 | 1,043 | 1,680 | N/A |
| 12/31/2019 | 4,470 | 715 | 1,049 | 1,507 | N/A |
| 9/30/2019 | 4,681 | 1,025 | 1,067 | 1,479 | N/A |
| 6/30/2019 | 4,741 | 1,301 | 1,238 | 1,599 | N/A |
| 3/31/2019 | 4,714 | 1,364 | 1,178 | 1,475 | N/A |
| 12/31/2018 | 4,652 | 1,458 | 1,008 | 1,341 | N/A |
| 9/30/2018 | 4,587 | 1,508 | 1,174 | 1,494 | N/A |
| 6/30/2018 | 4,386 | 1,511 | N/A | 1,280 | N/A |
| 3/31/2018 | 4,308 | 1,491 | N/A | 1,336 | N/A |
| 12/31/2017 | 4,154 | 1,452 | N/A | 1,458 | N/A |
| 9/30/2017 | 4,106 | 1,451 | N/A | 1,406 | N/A |
| 6/30/2017 | 3,976 | 1,432 | N/A | 1,507 | N/A |
| 3/31/2017 | 3,891 | 1,415 | N/A | 1,557 | N/A |
| 12/31/2016 | 3,833 | 1,396 | N/A | 1,435 | N/A |
| 9/30/2016 | 3,739 | 1,380 | N/A | 1,503 | N/A |
| 6/30/2016 | 3,711 | 1,341 | N/A | 1,340 | N/A |
| 3/31/2016 | 3,610 | 1,310 | N/A | 1,170 | N/A |
| 12/31/2015 | 3,478 | 1,266 | N/A | 1,056 | N/A |
| 9/30/2015 | 3,467 | 1,217 | N/A | 972 | N/A |
| 6/30/2015 | 3,237 | 1,166 | N/A | 921 | N/A |
| 3/31/2015 | 3,015 | 1,102 | N/A | 978 | N/A |
| 12/31/2014 | 2,883 | 1,042 | N/A | 982 | N/A |
| 9/30/2014 | 2,686 | 989 | N/A | 877 | N/A |
| 6/30/2014 | 2,570 | 933 | N/A | 909 | N/A |
| 3/31/2014 | 2,450 | 883 | N/A | 761 | N/A |
| 12/31/2013 | 2,327 | 830 | N/A | 669 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002294's forecast earnings growth (15.5% per year) is above the savings rate (2.8%).
Earnings vs Market: 002294's earnings (15.5% per year) are forecast to grow slower than the CN market (26.2% per year).
High Growth Earnings: 002294's earnings are forecast to grow, but not significantly.
Revenue vs Market: 002294's revenue (14.9% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 002294's revenue (14.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002294's Return on Equity is forecast to be low in 3 years time (9.2%).